Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 16/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20049793 | 0.95 | TYK2 (0.39) | TYK2PDE4DTTKNTRK1CNR1 | |
| SCHEMBL20049795 | 0.94 | TYK2 (0.41) | TYK2PDE4DTTKNTRK1CNR1 | |
| SCHEMBL21175213 | 0.94 | TYK2 (0.42) | TYK2PDE4DTTKNTRK1 | |
| SCHEMBL20049790 | 0.90 | TYK2 (0.42) | TYK2PDE4DTTKNTRK1F10 | |
| SCHEMBL20049758 | 0.86 | TYK2 (0.42) | TYK2PDE4DTTKNTRK1CNR1 | |
| SCHEMBL21175158 | 0.85 | TYK2 (0.43) | TYK2PDE4DNTRK1CNR1CNR2 | |
| SCHEMBL20049749 | 0.84 | TYK2 (0.45) | TYK2PDE4DTTK | |
| SCHEMBL20049473 | 0.83 | TYK2 (0.43) | TYK2PDE4DCNR1CNR2 | |
| SCHEMBL24085369 | 0.83 | TYK2 (0.41) | TYK2PDE4DTTKNTRK1CNR1 | |
| SCHEMBL20049765 | 0.82 | TYK2 (0.46) | TYK2PDE4DTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523305-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2021-12-08 | — | — | EP | disclosed |
| US-10836770-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190225620-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2019-07-25 | — | — | US | disclosed |
| WO-2018067432-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225620-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, IL2, IFNAR1 | TYK2 1/4885PDE4D 2365/4885TTK 93/4885 |
| US-10836770-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses | TYK2, IL2, IFNAR1 | TYK2 1/4885PDE4D 2200/4885TTK 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.